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The frequent use of antibiotics is implicated as the most 
coninion cause of the development of resistance [l,2]. 
Resistance to quinolones was very rare when they were 
first introduced into clinical practice. However, an 
increase in resistance to fluoroquinolones has been 
recently observed, especially in developing countries, 
where strict rules for antibiotic usage have not yet 
been established [3,4]. In the present study, the in vitro 
activity of trovafloxacin (CP-99, 219) was evaluated 
against 632 clinical isolates and was compared with that 
of spartloxacin, ciprofloxacin, and ofloxacin. 
All bacteria used in the current study were 
recovered from clinical sources in the Clinical Micro- 
biology Laboratory, Hacettepe University Hospital, 
Ankara, Turkey The exceptions were iZloraxella catarrlzalis 
strains, which were kindly provided by Dr Bulent 
Siimerkan, Central Microbiology Laboratory, Erciyes 
University Hospital, Kayseri, Turkey. Escliericlzia coli, 
Serratiu spp., Klcbsiella spp., Enterohacter spp., Pseudo- 
itionus aertginosa and Stenotroplzornonas maltophilia strains 
were mostly blood isolates, and were identified by the 
API system (Bio-Merieux, France). Salmonella spp. and 
Sli[qella spp. were isolated from stool cultures, and their 
identification was confirmed by agglutination with 
specific antisera (Difco Laboratories, USA). Pvoteus 
strains were recovered from pus and urine samples. 
Streptococcus pneurnoniae and staphylococci were isolated 
from blood, pus and sterile body sites of hospitalized 
patients. Methicillin resistance in staphylococci was 
determined by using oxacillin disks in Mueller-Hinton 
agar, following the NCCLS guidelines. Enterococcus 
spp. were isolated from various clinical specimens 
from patients with hospital- or community-acquired 
infections and were identified according to their bio- 
chemical reactions, as previously described [S]. 
Trovafloxacin was supplied by Pfizer Central 
Kesearch, USA, ciprofloxacin by Bayer, Turkey, 
sparfloxacin by EczacibapKhone Pouleiic, Turkey, and 
ofloxacin by Hoechst, Turkey. All agents were supplied 
as powders, which were diluted according to the 
manufacturers' instructions. Mininial inhibitory concen- 
trations (MICs) were determined on Mueller-Hinton 
agar (Merck, Germany) which contained doubling 
dilutions of antibiotics according to NCCLS criteria 
[6] .  A niultipoint inoculator (Denley UK) was used to 
inoculate 1 O 4  CFU bacteria per spot. The results were 
read after 18 h of incubation. All the antibiotics were 
tested at the same time. 
The MICso and MIC9o values for the isolates 
are summarized in Table 1. Trovafloxacin and other 
quinolones had sirmlar in vitro activity against Escliericliia 
coli. In addition, the MICro values of all the quinolones 
tested against Enterohactcr spp. and Klehsiellu spp. 
exceeded their susceptibility breakpoints. The MIC50 
values of all agents were also comparable. The activities 
of the quinolones against Profetrs spp. were similar 
(MICgo 1-2 mg/L), with the exception of sparfloxacin 
(MICgo, 8 nig/L). Trovafloxacin had an in vitro activity 
similar to that of ofloxacin against Pseudorizonns aeru~qinosa, 
but ciprofloxacin was the most potent antibiotic against 
this organism. Although Stenotvophotnonas ninltopliilia 
strains are usually resistant to many antimicrobial agentc, 
50% of these strains were inhibited by all four quino- 
lones tested. Ciprofloxacin was the only agent that 
inhibited 90% of the strains in Serratia isolates. All 
fluoroquinolones had low MICs (range 10.008- 
2 mg/L) against Salmonella spp. and Slikella spp. and 
resistance was not observed for any of the quinolones. 
Trovafloxacin was more active in vitro against 
Streptococcus pneumoriiac than ciprofloxacin and ofloxacin, 
and its M I C ~ O  value was eight-fold lower than that of 
ciprofloxacin. The second most active quinolone against 
pneuniococci was sparfloxacin. Of  these strains, nine 
(1 8%) were intermediately resistant to penicillin and 
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Table 1 In vitro activity of trovafloxacin and other fluoroquinolones against Gram-negative and Gram-positive pathogens 
MIC (mg/L) 
Organism Antimicrobial 
(number of strains) agent 50% 90% Range 
Escherichia coli 
(49) 
Err tero bacter spp. 
(54) 
Pruteus mirabilis 
(34) 
Pruteus vulgaris 
(13) 
Salmonella spp. 
(41) 
Serratia spp. 
(61) 
Stenotrophomonas 
mnltophilia 
(29) 
Streptococcus 
pneumoniae 
(49) 
Epiterococcus spp. 
(40) 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Spadoxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
Trovafloxacin 
Sparfloxacin 
Ciprofloxacin 
Ofloxacin 
0.03 
0.03 
10.008 
0.03 
0.125 
0.06 
0.06 
0.12s 
0.25 
0.06 
0.06 
0.125 
0.50 
0.25 
0.03 
0.12s 
0.50 
0.50 
0.03 
0.125 
2 
4 
0.50 
2 
0.06 
0.03 
0.01 
0.06 
2 
2 
0.25 
0.50 
0.03 
0.01 
10.008 
0.01 
0.50 
0.50 
1 
1 
0.06 
0.125 
0.50 
0.50 
0.125 
0.50 
1 
1 
0.125 
0.25 
0.25 
0.25 
> 16 
> 16 
4 
> 16 
> 16 
> 16 
> 16 
16 
1.0 
1.0 
0.50 
2 
2 
8 
2 
1 
> 16 
> 16 
>16 
> 16 
0.25 
0.25 
0.125 
0.125 
4 
4 
1 
2 
0.12s 
0.2s 
0.06 
0.25 
2 
4 
4 
4 
0.125 
0.25 
1 
2 
1 
0.50 
2 
2 
50.008-2 
10.008-4 
50.008-2 
0.03-2 
0.125 to >16 
0.03 to >I6 
10.008 to >16 
0.03 to >16 
0.03 to >16 
0.03 to >I6 
0.01 to >16 
0.03 to >16 
s 0.008- 1 
0.01-4 
50.008-1 
50.008-2 
0.25-4 
0.01-16 
20.008-8 
0.08-16 
0.03 to >16 
0.01 to >16 
0.06 to >16 
10.008-8 
10.008-2 
50.008-1 
50.008-2 
10.008-1 
0.125-16 
0.03 to >16 
10.08-8 
0.03- 16 
10.008-1 
10.008-2 
10.008-0.25 
0.01-0.50 
0.125-8 
0.25-8 
0.125-8 
0.50-8 
0.01-2 
0.03-8 
0.50-4 
0.1258 
0.06-4 
0.125-4 
0.50-8 
0.50-8 
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Table 1 mntinued 
MIC (tng/L) 
O r g m i ~ i i i  Antimicrobial 
(number of ytrainrj agent 50% 'Ill%> 
. -  
Trovafloxacin 
Ciprofloxacin 
Ofloxacln 
Trovaflosacin 
Ciprofloxacin 
Ofloxdclll 
Trov~iflouacin 
Spdloxac in  
(:iproflosacin 
Odoxaciii 
Trovafloxacin 
Sparfloxacin 
(:iprofloxacin 
Otloxac1n 
Trovafloxaciii 
Sparfloxa~in 
Ciprofloxaciri 
Ofloxacn1 
~ ~ ~ r f l ~ ~ ~ ~ ~ ~ ~  
spamoxacltl 
5 0.008 
<i!.008 
i!.O1 
I!.Ol 
1 
8 
8 
8 
( ! . i l l  
I!.(!() 
0.25 
0.25 
i l . i O  
4 
- 
4 
11.03 
0.125 
il.12.S 
0.25 
0.25 
il.50 
0.50 
1 
two had high level resistance to penicillin. All quinolones 
showed equal in vitro activity against Movaxella caturrlialis, 
and MICsl, values were lower than their susceptibility 
breakpoints. Against enterococci, sparfloxacin was the 
agent with the lowest MIC~J(~ value (0.5 nig/L), followed 
by trovafloxacin (1 mg/L). Among staphylococci, strains 
re5ictant to  inethicillin were also resistant to the 
quinolones tested. Trovafloxacin was the only agent 
that inhibited 50% of the methicillin-resistant staphylo- 
cocci (1 ing/L). Furthermore, in niethicillin-susceptible 
strain?, trovafloxacin (MICU!, 0.25 nig/L) demonstrated 
two-fold greater activity than ciprofloxacin (MICo(l 
0..5 nig/L). 
The  current study indicates that a wide range of 
Grarn-negative and Gram-positive bacteria isolated 
from clinically important infections are susceptible to 
trovafloxacin. Furthermore. trovafloxacin \ yas  active 
against 50% of the metliicillin-resistant staphylococcal 
str'iins. 
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